Ovarian Cancer

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

Experts from the gynecologic oncology space vote on their most anticipated abstracts on OncLive’s social media.

Experts highlight key abstracts and presentations to keep an eye on in gynecologic oncology at the 2025 ASCO Annual Meeting.

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

Pembrolizumab/paclitaxel with or without bevacizumab improved PFS vs placebo/chemotherapy with or without bevacizumab in platinum-resistant ovarian cancer.

Rachel Grisham, MD, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated, recurrent low-grade serous ovarian cancer.

Premal Thaker, MD, MS, discusses prior data supporting the ongoing investigation of IMNN-001 plus perioperative chemotherapy in ovarian cancer.

Deena M. Atieh Graham, MD, discusses the FDA approval of mirvetuximab soravtansine.

Bradley Monk, MD, FACOG, FACS, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.

Deena M. Atieh Graham, MD, discusses ongoing studies of note in patients with ovarian cancer following World Ovarian Cancer Day.

Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

The FDA has granted accelerated approval to avutometinib plus defactinib (Avmapki Fakzynja) for select KRAS-mutated recurrent low-grade serous ovarian cancer.

Deena M. Atieh Graham, MD, highlights the current treatment paradigm in ovarian cancer, particularly PARP inhibitors and new ADCs in the space.

Elizabeth Lee, MD, discusses the need for FRα-targeted therapies with differing payloads for patients with platinum-resistant ovarian cancer.

Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.

Fiona Simpkins, MD, discusses key findings from the phase 2 DENALI trial evaluating azenosertib in patients with platinum-resistant ovarian cancer.

INX-315 has received FDA fast track designation for the treatment of patients with CCNE1-amplified, platinum-resistant or refractory ovarian cancer.

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

Elizabeth K. Lee, MD, discusses data from the phase 1/2 RAINFOL-01 study of Rina-S in advanced ovarian cancer.

Hyun Woong Cho, MD, PhD, explains the rationale for assessing niraparib/bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Fiona Simpkins, MD, discusses the use of cyclin E1 positivity as a biomarker of azenosertib response in platinum-resistant ovarian cancer.

Hyun-Woong Cho, MD, PhD, highlights the efficacy of niraparib/bevacizumab as maintenance therapy in platinum-sensitive, recurrent ovarian cancer.

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.